查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917895

RNA分析市场－2026-2031年预测

RNA Analysis Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

RNA 分析市场预计将从 2025 年的 55.72 亿美元成长到 2031 年的 112.69 亿美元，复合年增长率为 12.45%。

RNA分析市场是生命科学和诊断产业中一个基础且快速成长的细分市场，涵盖了用于研究核糖核酸（RNA）分子的各种技术和调查方法。该市场对现代生物医学研究至关重要，有助于理解基因表现、调控和功能。对编码mRNA、非编码RNA和复杂转录组的分析，能够为细胞过程、疾病机制和治疗标靶提供关键资讯。市场成长的驱动力在于其在许多高影响力领域发挥的关键作用，例如推进肿瘤学研究、应对感染疾病威胁、实现个人化医疗，以及推动蓬勃发展的基于RNA的治疗发现和开发领域。

RNA分析在肿瘤学中扮演着至关重要的角色，是推动肿瘤学发展的重要且强大的因素。转录组学研究，例如RNA定序（RNA-Seq）技术，是癌症研究和精准肿瘤学的基础。这些技术能够识别疾病特异性基因表现特征，发现用于诊断和预后的新型生物标记，并检测驱动肿瘤发生的基因融合和剪接变异。这种分子谱分析对于理解肿瘤异质性和抗药性机制以及开发标靶治疗至关重要。持续严峻的全球癌症负担导致对先进RNA分析工具的需求不断增长，以支持基础研究和临床应用研究。

同时，感染疾病监测和疫情应对领域的应用正推动着强劲的市场成长动能。病原体RNA分析对于识别和表征病毒、细菌和其他传染性病原体、阐明其毒力和传播机制以及追踪基因组进化至关重要。这项能力在新冠肺炎疫情期间得到了充分展现，并且对于持续监测地方性流行病原体和新发病原体仍然至关重要。 RNA分析有助于疫苗研发、抗病毒药物发现以及宿主-病原体相互作用的研究，使其成为全球公共卫生和研究机构的关键工具。

个人化医疗的快速发展是市场扩张的主要驱动力。向个人化医疗的转变高度依赖分子数据。 RNA表现谱分析正被越来越多地用于患者分层、预测治疗反应以及识别最有可能从特定标标靶治疗或免疫疗法中获益的患者。这项应用在肿瘤学领域尤为突出，但正在扩展到其他治疗领域，从而催生了对稳健、可重复且通常经过临床检验的RNA分析平台的需求，这些平台能够提供可操作的见解来指导治疗决策。

或许最具活力的成长要素是基于RNA疗法开发的爆炸性成长。 mRNA疫苗的成功应用证明了该平台的有效性，并刺激了对更广泛的RNA药物的大规模投资，包括治疗性mRNA、 RNA干扰（RNAi）药物、反义寡核苷酸以及依赖嚮导RNA的CRISPR技术。这些疗法的整个生命週期，从标靶识别和检验到动态物标记评估和治疗反应监测，都高度依赖先进的RNA分析技术。这直接推动了生物製药研发过程中对分析工具、试剂和服务的需求。

此外，公共和私营部门对基础研究和转化研究的持续大规模投资也推动了市场发展。政府资助机构、学术机构和生物技术公司正在进行广泛的研究，以揭示转录组的复杂性，了解健康和疾病状态下的RNA生物学，并开发新的分析方法。这些研究工作通常得到国家和国际基因组学计划的支持，确保了创新源源不断，并带动了RNA分析产品和服务的持续成长。

从地理位置来看，北美在市场中占据主导地位。这一主导地位得益于许多主要学术研究中心的集中、强大的生物技术和製药产业、充足的研发资金以及对尖端基因组技术的早期应用。该地区先进的临床试验和分子诊断基础设施进一步巩固了其作为RNA分析高级应用领先中心的地位，无论是在研究领域还是在临床开发领域。

竞争格局包括成熟的生命科学工具公司、专业的基因组学公司和整合解决方案提供者。关键的竞争和创新领域集中在提高RNA-Seq平台的灵敏度、通量和多重定序能力，简化和自动化样品製备流程，降低单一样本的成本，以及开发用户友好的生物资讯软体用于数据分析和解读。提供从样本製备到资料解读的端到端解决方案的能力是关键的差异化优势。

总之，RNA分析市场正经历强劲成长，这得益于其在解决现代医学和药物研发中面临的紧迫挑战方面发挥的核心作用。其发展轨迹与精准医学的进步和RNA疗法的革命密切相关。未来市场发展将受到以下技术创新的影响：高品质转录组数据的普及化、临床应用方法的标准化以及人工智慧在数据解读中的持续应用。随着我们对RNA生物学理解的不断加深及其治疗潜力的进一步挖掘，对先进、可靠且扩充性的RNA分析工具的需求将持续增长，从而巩固其作为21世纪生物医学研究重要支柱的地位。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议
  • 正在研发中的产品

第四章 技术展望

第五章 RNA分析市场（按类型划分）

  • 介绍
  • 传讯RNA（mRNA）
  • 转移RNA（tRNA）
  • 其他的

第六章 RNA分析市场：依应用领域划分

  • 介绍
  • 试剂
  • 成套工具
  • 酵素
  • 其他的

第七章 RNA分析市场（按最终用户划分）

  • 介绍
  • 製药和生物技术公司
  • 学术和研究机构
  • 其他的

第八章：按地区分類的RNA分析市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Promega Corporation
  • Lexogen
  • Zymo Research
  • Azenta US, Inc
  • Shimadzu
  • Cofactor Genomics
  • Parse Biosciences
  • CD Genomics
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615904

RNA Analysis Market, with a 12.45% CAGR, is projected to increase from USD 5.572 billion in 2025 to USD 11.269 billion in 2031.

The RNA analysis market is a foundational and rapidly expanding segment within the life sciences and diagnostics industry, encompassing a broad suite of technologies and methodologies for studying ribonucleic acid (RNA) molecules. This market is central to modern biomedical research, enabling the exploration of gene expression, regulation, and function. The analysis of coding mRNA, non-coding RNAs, and complex transcriptomes provides critical insights into cellular processes, disease mechanisms, and therapeutic targets. Market growth is propelled by its indispensable role in several high-impact areas: advancing oncology research, responding to infectious disease threats, enabling personalized medicine, and fueling the burgeoning field of RNA-based therapeutic discovery and development.

A primary and powerful driver is the critical role of RNA analysis in oncology. The study of the transcriptome through techniques like RNA sequencing (RNA-Seq) is fundamental to cancer research and precision oncology. It enables the identification of disease-specific gene expression signatures, the discovery of novel biomarkers for diagnosis and prognosis, and the detection of fusion genes and splice variants that drive tumorigenesis. This molecular profiling is essential for understanding tumor heterogeneity, mechanisms of drug resistance, and for developing targeted therapies. The persistent and significant global burden of cancer ensures sustained and growing demand for sophisticated RNA analysis tools to support both basic research and clinical translational efforts.

Concurrently, the market is strongly driven by its application in infectious disease research and outbreak response. The analysis of pathogen RNA is crucial for identifying and characterizing viruses, bacteria, and other infectious agents, understanding their virulence and transmission mechanisms, and tracking genomic evolution. This capability was prominently demonstrated during the COVID-19 pandemic and remains vital for ongoing surveillance of endemic and emerging pathogens. RNA analysis supports vaccine development, antiviral drug discovery, and the study of host-pathogen interactions, making it a critical tool for public health agencies and research institutions worldwide.

The accelerating focus on personalized medicine is a major catalyst for market expansion. The shift toward tailoring medical treatment to the individual characteristics of each patient relies heavily on molecular data. RNA expression profiling is increasingly used to stratify patients, predict treatment response, and identify those most likely to benefit from specific targeted therapies or immunotherapies. This application, particularly prominent in oncology but expanding to other therapeutic areas, creates demand for robust, reproducible, and often clinically validated RNA analysis platforms that can deliver actionable insights to guide therapeutic decisions.

Perhaps the most dynamic growth vector is the explosion in RNA-based therapeutic development. The successful deployment of mRNA vaccines has validated the platform and catalyzed massive investment in a broader spectrum of RNA medicines, including therapeutic mRNAs, RNA interference (RNAi) drugs, antisense oligonucleotides, and CRISPR-based technologies reliant on guide RNAs. The entire lifecycle of these therapeutics-from target identification and validation to pharmacodynamic biomarker assessment and monitoring treatment response-is deeply dependent on advanced RNA analysis. This directly fuels demand for analytical tools, reagents, and services across the biopharmaceutical R&D continuum.

Furthermore, the market benefits from substantial and sustained investment in basic and translational research from both public and private sectors. Government funding agencies, academic institutions, and biotechnology companies are conducting extensive research to unravel the complexities of the transcriptome, understand RNA biology in health and disease, and develop novel analytical methods. These initiatives, often supported by national and international genomics programs, ensure a continuous pipeline of innovation and a high volume of consumption for RNA analysis products and services.

Geographically, North America maintains a dominant market position. This leadership is underpinned by a concentration of leading academic research centers, a robust biotechnology and pharmaceutical sector, substantial R&D funding, and early adoption of cutting-edge genomic technologies. The region's well-developed infrastructure for clinical trials and molecular diagnostics further reinforces its role as the primary hub for advanced RNA analysis applications in both research and developing clinical contexts.

The competitive landscape includes established life science tools companies, specialized genomics firms, and providers of integrated solutions. Key areas of competition and innovation focus on improving the sensitivity, throughput, and multiplexing capabilities of RNA-Seq platforms; simplifying and automating library preparation workflows; reducing costs per sample; and developing user-friendly bioinformatics software for data analysis and interpretation. The ability to offer end-to-end solutions-from sample preparation to data insight-is a significant differentiator.

In conclusion, the RNA analysis market is experiencing robust growth fueled by its central role in addressing some of the most pressing challenges in modern medicine and drug discovery. Its trajectory is inextricably linked to the progress of precision medicine and the RNA therapeutic revolution. Future market development will be shaped by technological advancements that democratize access to high-quality transcriptomic data, the standardization of methods for clinical application, and the continued integration of artificial intelligence for data interpretation. As our understanding of RNA biology deepens and its therapeutic potential is further unlocked, the demand for sophisticated, reliable, and scalable RNA analysis tools will continue to expand, solidifying its status as an essential pillar of 21st-century biomedical science.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

RNA Analysis Market Segmentation

  • By Type
  • Messenger RNA (mRNA)
  • Transfer RNA (tRNA)
  • Others
  • By Application
  • Reagnet
  • Kits
  • Enzymes
  • Others
  • By End-User
  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. RNA ANALYSIS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Messenger RNA (mRNA)
  • 5.3. Transfer RNA (tRNA)
  • 5.4. Others

6. RNA ANALYSIS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Reagnet
  • 6.3. Kits
  • 6.4. Enzymes
  • 6.5. Others

7. RNA ANALYSIS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotech Companies
  • 7.3. Academic & Research Institutes
  • 7.4. Others

8. RNA ANALYSIS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Promega Corporation
  • 10.2. Lexogen
  • 10.3. Zymo Research
  • 10.4. Azenta US, Inc
  • 10.5. Shimadzu
  • 10.6. Cofactor Genomics
  • 10.7. Parse Biosciences
  • 10.8. CD Genomics
  • 10.9. Thermo Fisher Scientific Inc.
  • 10.10. Illumina, Inc.
  • 10.11. F. Hoffmann-La Roche Ltd
  • 10.12. QIAGEN
  • 10.13. Bio-Rad Laboratories, Inc.
  • 10.14. Danaher Corporation
  • 10.15. Agilent Technologies, Inc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations